Vol. 2 No. 6 (2022)
Reimbursement Recommendations

Upadacitinib (Rinvoq)

Published June 24, 2022

Key Messages

  • CADTH recommends that Rinvoq be reimbursed by public drug plans for the treatment of adults and adolescents 12 years of age and older with refractory moderate to severe atopic dermatitis (AD) if certain conditions are met.
  • Rinvoq should only be covered to treat patients who have previously tried and are refractory to, or who are ineligible or cannot tolerate, the highest tolerated dose of topical treatments for AD combined with phototherapy (where available), and at least 1 of methotrexate, cyclosporine, mycophenolate mofetil, or azathioprine.
  • Rinvoq should only be reimbursed if prescribed by a dermatologist, allergist, clinical immunologist, or pediatrician, and the cost of Rinvoq is reduced.